Drugs · acquisition-cost intelligence
divalproex sodium
· ingredient valproate· DIVALPROEX SODIUM 250 mg/1; DIVALPROEX SODIUM 500 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.16834
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other valproate products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Valproic Acid | $0.03316 | −$0.13520 |
| Depakote | $0.08917 | −$0.07920 |
| Depakote ER | $0.18706 | +$0.01870 |
| divalproex sodium | $0.18706 | +$0.01870 |
| Depakote Sprinkles | $0.19861 | +$0.03030 |
| Valproic | $0.23989 | +$0.07160 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.